Seattle Genetics to Present at the J.P. Morgan Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 10:30 a.m. Pacific Time. Both the presentation and question and answer session that follows at 11:00 a.m. will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

About Seattle Genetics

Seattle Genetics is an innovative biotechnology company dedicated to improving the lives of people with cancer through novel antibody-based therapies. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS® (brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas. The company is also advancing a robust pipeline of novel therapies for solid tumors and blood-related cancers designed to address significant unmet medical needs and improve treatment outcomes for patients. More information can be found at www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171219005304/en/

Seattle Genetics, Inc.
Investors:
Peggy Pinkston, 425-527-4160
[email protected]
or
Media:
Brandi Robinson, 425-527-2910
[email protected]

Source: Seattle Genetics, Inc.

You May Also Be Interested In

• Saab Q2 results 2026: Strong order bookings reinforce market position
• Danske Bank A/S revises 2026 net profit outlook upwards. Now expects a net profit in the range of DKK 23-25 billion
• Volvo Cars Q2 2026: executing in a very challenging environment